Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhinovirus-targeted nasal spray
- Development stage
- Preclinical
- Lead developer
- Applied Biological Laboratories
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
Applied Biological Laboratories is developing an intranasal rhinovirus-targeted treatment composed of a soluble intercellular adhesion molecule 1 competitive inhibitor approach together with immune-modulating proteins. The spray is intended to prevent or reduce rhinovirus infection by competitively blocking viral attachment at the rhinovirus receptor-binding site while enhancing local innate mucosal antiviral responses. The program is described as IND-enabling for rhinovirus infection and the common cold.
- Other names
- Rhinovirus-targeted nasal spray (competitive inhibitor + immune-modulating proteins)rhinovirus-targeted nasal spraysICAM-1 targeted nasal spraysICAM1 targeted nasal spraysICAM 1 targeted nasal spray
Beyond the preview
Go deeper on rhinovirus-targeted nasal spray.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhinovirus-targeted nasal spray.